Latest Stocks: Enanta Pharmaceuticals Inc (ENTA) Rating Lowered to Sell at Zacks Investment Research

Latest Stocks: Enanta Pharmaceuticals Inc (ENTA) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) from a hold rating to a sell rating in a report published on Friday, May 12th.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Enanta Pharmaceuticals (ENTA) opened at 30.23 on Friday. The firm has a 50-day moving average of $31.45 and a 200 day moving average of $31.42. The firm’s market cap is $576.88 million. Enanta Pharmaceuticals has a 1-year low of $20.79 and a 1-year high of $37.31. Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.10. The firm had revenue of $9 million for the quarter, compared to the consensus estimate of $9.19 million. Enanta Pharmaceuticals had a negative net margin of 18.92% and a negative return on equity of 3.54%. The business’s quarterly revenue was down 30.8% on a year-over-year basis. During the same period last year, the company posted ($0.09) EPS. Analysts expect that Enanta Pharmaceuticals will post ($0.05) earnings per share for the current fiscal year.

Enanta Pharmaceuticals (ENTA) opened at 30.23 on Friday. The firm has a 50-day moving average of $31.45 and a 200 day moving average of $31.42. The firm’s market cap is $576.88 million. Enanta Pharmaceuticals has a 1-year low of $20.79 and a 1-year high of $37.31. Several hedge funds have recently bought and sold shares of ENTA. WFG Advisors LP increased its stake in Enanta Pharmaceuticals by 3,243.2% in the fourth quarter. WFG Advisors LP now owns 1,471 shares of the biotechnology company’s stock worth $109,000 after buying an additional 1,427 shares during the period. Mason Street Advisors LLC increased its stake in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $204,000. Glassman Wealth Services acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $223,000. Finally, Bayesian Capital Management LP acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $234,000. Institutional investors own 71.61% of the company’s stock.

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment